NeutriSci International Inc. enters into a major R&D Memorandum of Understanding with Scientus Pharma Inc. Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing retail distribution networks across Canada. The core ingredients in NeutriSci's products have significant anti-oxidant properties and health benefits. Scientus Pharma will conduct research on Neutrisci's products and their components in combination with various cannabinoids. Research activities will initially be funded by NeutriSci. Both companies will have rights for further product development and testing, including potentially preclinical and clinical trials, which may be co-funded.